netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Chapter Links...
 Details...
08.03.04.02  Expand sub section  Prostate cancer and gonadorelin analogues
Radium-223 dichloride
(Xofigo®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
  • Provided by radiotherapy department in accordance with NICE
 
Link  NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Link  MHRA Drug Safety Update (December 2017): Radium-223 dichloride (Xofigo▼): do not use in combination with abiraterone and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures  
 
08.03.04.02  Expand sub section  Gonadorelin analogues
 note 

Clinicians are encouraged to prescribe the least expensive product that is clinically appropriate.

Goserelin
View adult BNF View SPC online View childrens BNF
First Choice
Green plus
  • Approved formulations include 3.6mg and 10.8mg implants.
 
Leuprorelin Acetate
View adult BNF View SPC online View childrens BNF
First Choice
Green plus
  • Approved formulations include leuprorelin 3.75mg & 11.25mg prefilled syringes.
 
Triptorelin
View adult BNF View SPC online View childrens BNF
First Choice
Green plus

  • Approved formulations include triptorelin 3mg, 11.25mg and 22.5mg IM injection for the treatment of prostate cancer

  • Please note for the treatment of precocious puberty please refer to Chapter 6 Drugs affecting gonadotrophins

 
Degarelix
View adult BNF View SPC online View childrens BNF
First Choice
Green plus
  • Approved formulations include 80mg and 120mg vials (with diluent).
  • Approved for the first line treatment of advanced hormone dependant prostate cancer with a PSA > 20ng/l at presentation 
    • -approved as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases in line with NICE.

 
Buserelin
(Prostate)
View adult BNF View SPC online View childrens BNF
Alternatives
Green plus
  • Approved formulations include:
    • 5mg in 5ml injection;
    • 150 microgram metered dose nasal spray.

 
 
08.03.04.02  Expand sub section  Anti-androgens
Abiraterone
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
  • Approved for castration-resistant metastatic prostate cancer in line with NICE.
  • Approved for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in line with NICE and NHS England Commissioning Policy.
 
Link  NICE TA259: Abiraterone for castration resistant prostate cancer
Link  NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
 
Apalutamide  (Erleada®)
View adult BNF View SPC online View SMC online View childrens BNF
Formulary
Red
BlueTeq
  • 60mg tablets
  • Approved for treating hormone‑relapsed non‑metastatic prostate cancer that is at high risk of metastasising in adults in line with NICE
  • Approved for treating hormone-sensitive metastatic prostate cancer in adults in line with NICE, only if:
    • docetaxel is not suitable

 

 
Link  NICE TA740: Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer
Link  NICE TA741: Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
 
Bicalutamide
View adult BNF View SPC online View childrens BNF
Formulary
Green plus

Initiate with specialist advice.

 
 
Cyproterone
View adult BNF View SPC online View childrens BNF
Formulary
Green plus
 
 
Darolutamide (Nubeqa®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England
BlueTeq
  • 300mg tablets
  • Approved for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease in line with NICE
  • Approved with andorgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer in line with NICE

 

 
Link  NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
Link  NICE TA903: Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer
 
Enzalutamide
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • Approved for use in adults with metastatic hormone-relapsed prostate cancer, who have not had chemotherapy in line with NICE.
  • Approved for treating hormone-sensitive metastatic prostate cancer in line with NICE
 
Link  NICE TA316: Enzalutamide for prostate cancer
Link  NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Link  NICE TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer
 
Flutamide
(UNDER REVIEW)
View adult BNF View SPC online View childrens BNF
Formulary
Green plus
 
 
08.03.04.02  Expand sub section  Radiopharmaceuticals
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician and the drug should be supplied through the hospital throughout the duration of treatment. In some very exceptional circumstances (e.g. due to distance from the hospital, storage, supply or mobility/transport problems) it may be appropriate for the GP to be asked to prescribe a Red drug. This should be negotiated on an individual patient basis and should only be done with the GP’s prior informed agreement where the roles of the GP and hospital services are clearly defined and agreed. The GP should not feel under pressure to prescribe in these circumstances. For all RED drugs automatically added to the formulary in response to a positive NICE TA: Prescribers need to ensure that local Trust new drug governance procedures and pharmacy processes are followed before any prescribing.  

Amber

Drugs initiated by hospital specialist, but where continuing treatment by GPs may be appropriate under a shared care arrangement. The specialist should send the GP a copy of the shared care agreement to sign. The GP should sign the shared care agreement, or indicate they do not want to be part of such an agreement, and return a copy back to the specialist. Shared care guidelines are available or are being developed for most of the drugs listed as Amber. If no shared care guideline is available, the hospital specialist should provide the patient’s GP with sufficient information and support to allow treatment to be continued and managed safely in primary care.  

Green plus

Drugs normally recommended or initiated by a specialist (hospital or GP with an extended role https://www.rcgp.org.uk/gpwer), but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case. Provision of additional information, or an information leaflet, may be appropriate in some cases to facilitate continuing treatment by GPs.  

Green

Drugs where prescribing by GPs is appropriate. Can be initiated and prescribed in all care settings, and if appropriate, discontinued without recourse to secondary care.  

Black

NOT APPROVED: Drugs that have been considered by NTAG or the NENC ICB Medicines Subcommittee (or other approved body) and are not approved for prescribing within the North East and North Cumbria.   

Brown

UNDER REVIEW: drugs whose current formulary status or RAG status is currently under review.  

Not Recomended

NOT REVIEWED: Drugs that haven not been reviewed yet. This usually means that an application is in progress. These drugs are not normally considered appropriate for prescribing in the North East and North Cumbria until such time that a decision is taken on their formulary status.  

netFormulary